GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Debt-to-EBITDA

Ablynx NV (XBRU:ABLXS) Debt-to-EBITDA : -0.57 (As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ablynx NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was €0.00 Mil. Ablynx NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was €88.72 Mil. Ablynx NV's annualized EBITDA for the quarter that ended in Dec. 2017 was €-155.78 Mil. Ablynx NV's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2017 was -0.57.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ablynx NV's Debt-to-EBITDA or its related term are showing as below:

XBRU:ABLXS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.64   Med: -0.05   Max: 10.23
Current: -0.91

During the past 12 years, the highest Debt-to-EBITDA Ratio of Ablynx NV was 10.23. The lowest was -1.64. And the median was -0.05.

XBRU:ABLXS's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.36 vs XBRU:ABLXS: -0.91

Ablynx NV Debt-to-EBITDA Historical Data

The historical data trend for Ablynx NV's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Debt-to-EBITDA Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.01 -1.64 10.23 -0.91

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 1.52 -2.23 - -0.57

Competitive Comparison of Ablynx NV's Debt-to-EBITDA

For the Biotechnology subindustry, Ablynx NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Debt-to-EBITDA falls into.



Ablynx NV Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ablynx NV's Debt-to-EBITDA for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 88.715) / -98.071
=-0.90

Ablynx NV's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2017 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 88.715) / -155.78
=-0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2017) EBITDA data.


Ablynx NV  (XBRU:ABLXS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ablynx NV Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV (XBRU:ABLXS) Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines